Fresenius partners with WuXi Biologics to expand biosimilar drug portfolio

• Fresenius SE has agreed to partner with WuXi Biologics to expand its biosimilar drug portfolio.
• The collaboration aims to develop biosimilar candidates that could reach the market in the next decade.
• This partnership could potentially more than double Fresenius' current biosimilar portfolio.
• The agreement was announced by EQS-News and reported by Bloomberg and Financial Times.
• The collaboration focuses on the exclusive development of biosimilars.